III. Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-15 (Cancelled).

Claim 16 (Previously Presented): An anti-tumor composition comprising
an anti-tumor amount of anti-neoplastic agent;
a side effect-reducing amount of a shark cartilage extract; and
a pharmaceutically acceptable carrier.

Claim 17 (Currently Amended): The anti-tumor composition of claim 16 ~~1~~, wherein the anti-neoplastic agent is selected from the group consisting of busulfan, thiotepa, chlorambucil, cyclophosphamide, estramustine sodium phosphate, ifosfamide, mechlorethamine hydrochloride, melphalan, carmustine, lomustine, streptozocin, carboplatin, cisplatin, methotrexate sodium, cladribine, mercaptopurine, thioguanine, cytarabine, fluorouracil, hydroxyurea, daunorubicin, doxorubicin hydrochloride, epirubicin hydrochloride, idarubicin hydrochloride, dactinomycin, bleomycin sulfate, mitomycin, mitotane, mitoxantrone hydrochloride, etoposide, teniposide, docetaxel, paclitaxel, vinblastine sulfate, vincristine sulfate, vindesine sulfate, vinorelbine tartrate, altretamine, amsacrine, 1-asparaginase, dacarbazine, fludarabine phosphate, porfimer sodium, procarbazine hydrochloride, tretinoin (all-trans retinoic acid), marimastat, suramin, TNP 470, thalidomide and radiotherapeutics ~~radiotherapy~~.

Claim 18 (Previously Presented): The anti-tumor composition of claim 16, wherein the anti-neoplastic agent is cisplatin.

Claim 19 (Previously Presented): The anti-tumor composition of claim 16, wherein the shark cartilage extract comprises water-soluble molecules and a major portion of the water-soluble molecules have a molecular weight of less than about 500 kDa.

Claim 20 (Previously Presented): The anti-tumor composition of claim 19, wherein the shark cartilage extract has been prepared by fractionating a crude shark cartilage extract comprising water-soluble molecules obtained from shark cartilage material such that a major portion of the molecules having a molecular weight of greater than about 500 kDa is separated from a major portion of the molecules having a molecular weight of less than about 500 kDa.

Claim 21 (Previously Presented): The anti-tumor composition of claim 16, further comprising hypoxanthine.

Claim 22 (Previously Presented): An anti-tumor composition comprising

a sub-optimal dosage amount of an anti-neoplastic agent;

a side effect-reducing amount of a shark cartilage extract; and

a pharmaceutically acceptable carrier that is an aqueous solution,

wherein administration of the anti-tumor composition causes less side effects than administration of a similar composition that does not contain shark cartilage extract.

Claim 23 (Previously Presented): An anti-tumor composition comprising

an optimal dosage amount of an anti-neoplastic agent;

a side effect-reducing amount of a shark cartilage extract; and

a pharmaceutically acceptable carrier that is an aqueous solution,

wherein administration of the anti-tumor composition causes less side effects than administration of a similar composition that does not contain shark cartilage extract.

Claim 24 (Currently Amended): An anti-tumor treatment kit comprising

a first composition comprising a pharmaceutical dosage of an anti-neoplastic agent; and

a second composition comprising a side effect-reducing amount of a shark cartilage extract.

Claim 25 (Previously Presented): The anti-tumor treatment kit of claim 24, wherein the first composition and the second composition are each independently contained within a dosage form.

Claim 26 (Currently Amended): The anti-tumor treatment kit of claim 24, wherein the anti-neoplastic agent is selected from the group consisting of busulfan, thiotepa, chlorambucil, cyclophosphamide, estramustine sodium phosphate, ifosfamide, mechlorethamine hydrochloride, melphalan, carmustine, lomustine, streptozocin, carboplatin, cisplatin, methotrexate sodium, cladribine, mercaptopurine, thioguanine, cytarabine, fluorouracil, hydroxyurea, daunorubicin, doxorubicin hydrochloride, epirubicin hydrochloride, idarubicin hydrochloride, dactinomycin, bleomycin sulfate, mitomycin, mitotane, mitoxantrone hydrochloride, etoposide, teniposide, docetaxel, paclitaxel, vinblastine sulfate, vincristine sulfate, vindesine sulfate, vinorelbine tartrate, altretamine, amsacrine, 1-asparaginase, dacarbazine, fludarabine phosphate, porfimer sodium, procarbazine hydrochloride, tretinoin (all-trans retinoic acid), marimastat, suramin, TNP 470, thalidomide and radiotherapeutics ~~radiotherapy~~.

Claim 27 (Previously Presented): The anti-tumor treatment kit of claim 24, wherein the anti-neoplastic agent is cisplatin.

Claim 28 (Previously Presented): The anti-tumor treatment kit of claim 24, wherein the shark cartilage extract comprises water-soluble molecules, a major portion of which have a molecular weight of less than about 500 kDa.

Claim 29 (Previously Presented): The anti-tumor treatment kit of claim 24, wherein the shark cartilage extract has been prepared by fractionating a crude shark cartilage extract comprising water soluble molecules obtained from shark cartilage material such that a major portion of the molecules having a molecular weight of greater than about 500 kDa is separated from a major portion of the molecules having a molecular weight of less than about 500 kDa.

Claim 30 (Previously Presented): The anti-tumor treatment kit of claim 24, wherein the anti-neoplastic agent is present in a sub-optimal dosage amount and at least one of the first and second compositions further comprises a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is an aqueous solution, and administration of the compositions of the anti-tumor treatment kit causes less side effects than the administration of the compositions of a similar treatment kit that does not contain a composition containing shark cartilage extract.

Claim 31 (Previously Presented): The anti-tumor treatment kit of claim 24, wherein at least one of the first and second compositions further comprises a pharmaceutically acceptable carrier, wherein said pharmaceutically acceptable carrier is an aqueous solution, the anti-neoplastic agent is present in an optimal dosage amount, and administration of the compositions of the anti-tumor treatment kit causes less side effects than the administration of the compositions of a similar treatment kit that does not contain shark cartilage extract.

Claim 32 (Previously Presented): The anti-tumor treatment kit of claim 24, wherein the anti-neoplastic agent is cisplatin.

Claim 33 (Currently Amended): The anti-tumor treatment kit of claim ~~17~~ 24, wherein the first composition is contained within a parenteral dosage form and the second composition is contained within an oral dosage form.